Clinical Trial Update: A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TACE with durvalumab and bevacizumab in locoregional hepatocellular carcinoma is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Durvalumab (durvalumab)
• Transarterial chemoembolization (TACE)

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING